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Abstract
Background: Severe mental illness (SMI) is common, chronic and difficult to treat. Sleep and circadian dysfunctions
are prominent correlates of SMI, yet have been minimally studied in ways that reflect the complexity of the sleep
problems experienced. Prior treatment studies have been disorder-focused—they have treated a specific sleep
problem in a specific diagnostic group. However, real life sleep and circadianproblems are not so neatly
categorized, particularly in SMI where features of insomnia overlap with hypersomnia, delayed sleep phase and
irregular sleep-wake schedules. Accordingly, the aim of this studyprotocol is to test the hypothesis that a
Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) will improve functional impairment,
disorder-focused symptoms and sleep and circadian functioning. Participants across DSM diagnoses and across
common sleep and circadian problems are eligible. The elements of TranS-C are efficacious across SMI in research
settings with research-based providers. The next step is to test TranS-C in a community setting. Accordingly, this
study is being conducted within Alameda County Behavioral Health Care Services (ACBHCS), the Community
Mental Health Centre (CMHC) for Alameda County.
Methods/design: 120 adults diagnosed with SMI and sleep and circadian dysfunction within ACBHCS will be
randomly allocated to TranS-C (n = 60) or 6-months of Usual Care followed by Delayed Treatment with TranS-C
(UC-DT; n = 60). TranS-C is modularized and delivered across eight to twelve 50-minute, weekly, individual sessions.
All participants will be assessed before and immediately following treatment and again 6 months later. Primary
analysis will examine whether TranS-C significantly improves functional impairment, disorder-specific symptoms and
sleep and circadian functioning, relative to UC-DT. Exploratory analysis will examine whether improvements in sleep
and circadian functioning predict reduction in functional impairment and disorder-specific symptoms, and whether
the intervention effects are mediated by improved sleep and circadian functioning and moderated by previously
reported risk factors (demographics, symptom severity, medications, psychiatric and medical comorbidity).
(Continued on next page)
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Discussion: This trial tests an important and understudied mechanism—dysregulated sleep and circadian
rhythms—in SMI, a novel transdiagnostic treatment approach, in a community setting so as to contribute to the
goal of bridging the gap between research and practice.
Trial registration: ClinicalTrials.gov identifier: NCT02469233. Registered on 9 June 2015.
Keywords: Transdiagnostic, Sleep, circadian, Severe mental illness, Dissemination
Background
The number of people receiving a treatment for severe
mental illness (SMI) has risen [1–3], and health care
expenditures have skyrocketed [2]. Yet, less than half of
the treatments delivered have an evidence base [4–6], and
there is no evidence that available treatments decrease
disability [7]. Instead, the prevalence of mental illness is
increasing [8–10]. Accordingly, providing the large num-
ber of people with an SMI access to evidence-based treat-
ments requires fundamentally new approaches [11, 12].
One relatively new approach is to target research and
treatment at a transdiagnostic process. A transdiagnostic
process is defined, in mental health, as a clinical feature in
common across more than one mental illness [13–16].
The advantage of targeting research and treatment at a
transdiagnostic process is threefold. First, if a transdiag-
nostic process contributes to the maintenance of symp-
toms across multiple disorders, then one approach is to
develop treatments based on the process rather than on
the large number of discrete disorders currently listed in
the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5) [14]. Second, comorbid-
ity is the norm [17, 18]. Hence, a significant clinical
dilemma is which disorders to prioritize for treatment
[14]. Treating transdiagnostic processes provides one path
forward [13, 14]. Third, a transdiagnostic approach may
reduce the heavy burden on clinicians, who must learn
multiple disorder-focused protocols, by focusing on com-
mon theoretical underpinnings and interventions [13].
Sleep and circadian dysfunction has been highlighted as
a biologically [19] and theoretically [20] plausible trans-
diagnostic contributor to SMI [13], and a transdiagnostic
treatment for sleep and circadian disturbance has been
proposed [21]. The present study protocol tests the
hypothesis that the Transdiagnostic Intervention for Sleep
and Circadian Dysfunction (TranS-C) for participants
with SMI will improve functional impairment, disorder-
focused symptoms, and sleep and circadian dysfunction.
Why is sleep and circadian dysfunction important in SMI?
First, sleep and circadian dysfunction coexists with,
predates, and predicts SMI. Insomnia, hypersomnia, de-
layed sleep phase, and irregular sleep-wake schedules are
commonly comorbid with SMI [22–26]. The rate of
insomnia across DSM disorders is approximately 50%
[25]. The rate of hypersomnia is as high as 75% across
the mood disorders [26]. These problems often persist
even with best practice treatment for SMI [27–31].
Across multiple longitudinal studies, sleep and circadian
dysfunction predicts and predates the onset and worsen-
ing of SMI symptoms [32–41]. Second, sleep and circa-
dian dysfunction contributes to vicious cycles of mutually
reinforcing symptoms in SMI, including emotional
dysfunction [42, 43], poor health [44, 45], cognitive dys-
function [46, 47], and behavior problems [48, 49]. Third,
sleep and circadian dysfunction is modifiable in SMI. Cog-
nitive behavioral therapy for insomnia (CBT-I) effectively
treats insomnia that is comorbid with a wide range of
SMIs, including major depressive disorder [50], posttrau-
matic stress disorder [51–54], schizophrenia [55], bipolar
disorder [56, 57], alcohol dependence [58], and mixed
SMI [59–61]. There is evidence that these gains are well-
maintained following the cessation of treatment [62].
There is also evidence that treating insomnia improves the
symptoms of the comorbid disorder [50, 51, 55, 63]. In
our study, we will test a treatment that addresses an im-
portant and understudied transdiagnostic mechanism—
dysregulated sleep and circadian rhythms—in SMI. It also
addresses an understudied conceptual framework, namely
that sleep and circadian dysfunction contributes to vicious
cycles of escalating vulnerability and increased risk in SMI.
The majority of prior studies have been disorder-
focused—they have been designed to treat a specific sleep
problem (e.g., insomnia) in a specific diagnostic group
(e.g., depression, posttraumatic stress disorder). Real-life
sleep and circadian problems are not so neatly catego-
rized, particularly in SMI. Indeed, insomnia can overlap
with hypersomnia [26, 33, 64–67], delayed sleep phase
[68], and irregular sleep-wake schedules [28]. In a prior
study, CBT-I was modified to address the broader range
of sleep dysfunctions in SMI [56, 57], adding elements
from interpersonal and social rhythm therapy [69, 70],
chronotherapy [71], and motivational enhancement
[72–74]. Strong results reported by other groups [75]
and advice from dissemination experts [76, 77] led us
to develop a modularized transdiagnostic treatment [21].
Real-world setting: community mental health centers
There has been ample testing of sleep and circadian
interventions in specific disorders in research settings
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with research-based providers. Hence, the next step is to
conduct an “efficacy in the real world” study in commu-
nity settings with community-based providers while
maintaining the high level of control necessary to estab-
lish internal validity. This next step is important because
there is currently a 15- to 20-year lag between treatment
discovery and incorporating new treatments into routine
practice [12, 78]. Initial results indicate that providing
CBT-I in various real-world settings is effective [79–81].
Sleep health
The sleep health framework [82] underpins and guides
TranS-C. The sleep health framework prompts a shift
from a singular focus on the identification and treatment
of sleep disorders to a health promotion perspective,
which emphasizes universal attributes of sleep that can
be optimized to promote well-being. The sleep health
framework encourages sleep improvement along six
dimensions that have been linked to mental and physical
health outcomes [82]. The dimensions are (a) regularity of
sleep and waking up; (b) satisfaction with sleep or sleep
quality; (c) alertness during waking hours or daytime
sleepiness; (d) appropriate timing of the patient’s sleep
within a 24-h day; (e) sleep efficiency (i.e., the ability to
sleep for a large percentage of the time in bed), as indi-
cated by ease of falling asleep at the beginning of the night
and the ease of returning to sleep after awakenings across
the night; and (f) sleep duration, which is the total amount
of sleep obtained by the patient per 24 h.
The main aim of this study protocol is to evaluate the
effects of TranS-C vs. usual care followed by delayed treat-
ment with TranS-C (UC-DT) on functional impairment,
disorder-focused symptoms, and sleep and circadian func-
tion in participants receiving treatment for SMI in a
community mental health center. The hypothesis tested is
that TranS-C will be superior to UC-DT at posttreatment
and 6-month follow-up for functional impairment,
disorder-focused symptoms, and sleep and circadian
function.
In exploratory analyses, we will address (a) whether
improved sleep and circadian functioning predicts
reduced functional impairment and disorder-focused
symptoms, regardless of treatment condition; (b)
whether improved sleep and circadian functioning medi-
ates the intervention effects (TranS-C vs. UC-DT) on
functional impairment and disorder-focused symptoms;
and (c) whether intervention effects are moderated by
previously reported risk factors.
Methods/design
Study design and setting
We are conducting a prospective randomized controlled
study. Adults (n = 120) who meet criteria for SMI and
sleep and circadian dysfunction will be randomly
assigned, in a 1:1 parallel-group design, to undergo
TranS-C (n = 60) or UC-DT (n = 60) (see Fig. 1 for study
design flowchart). Randomization is stratified by psych-
osis (yes or no) and age (older or younger than 49 years).
Participants will receive a battery of outcome measures
pretreatment and again at posttreatment (i.e., 9–14
weeks later) and at 6-month follow-up. Those in the
UC-DT group will receive two additional assessments:
9–14 weeks and 6 months into UC-DT. An additional
assessment of sleep and circadian function will take
place in session 4 for the mediation analysis.
The assessment and therapy teams are blinded to
treatment allocation. Randomization will be conducted
using a computerized random number generator where
Fig. 1 Flowchart of study design
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the planned stratification randomization is part of the
allocation sequence. Only the statistician (LD), the pro-
ject coordinator, and the assigned therapist know the
treatment allocation of each participant. Participants are
financially compensated for their time. A Data and
Safety Monitoring Board will review the study every
6 months during the active treatment phase. A Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT 2013) checklist (see Additional file 1) and
figure (see Table 1) are provided [83].
For participants who discontinue, the assessment team
will endeavor to collect all assessment data, prioritizing
the primary outcomes.
Participants
A total of 120 adults who meet criteria for SMI and sleep
and circadian dysfunction are recruited from multiple sites
within Alameda County Behavioral Health Care Services
(ACBHCS; Alameda County, CA, USA). To date, these
sites are Oakland Community Support Center (Oakland),
Eden Mental Health Services (San Leandro), Tri City
Community Support Center (Fremont), Alameda Support
Center (Alameda), Axis Community Health (Pleasanton),
La Familia Counseling (Hayward), and multiple board and
care homes. Participants are referred via ACBHCS case
managers and doctors. The inclusion and exclusion cri-
teria are presented below. To enhance representativeness
and generalizability, the inclusion and exclusion criteria
are kept to a minimum.
Inclusion criteria
The inclusion criteria are as follows:
 Aged 18+ years
 English language fluency
 Presence of at least one DSM-5 mental disorder for
12 months
 One or more of the following sleep or circadian
problems for 3 months assessed with the
Sleep and Circadian Problems Interview:
– ≥30 minutes to get to sleep on three or more
nights per week
– Waking in the middle of the night for
≥30 minutes on three or more nights per week
– Obtaining <6 h of sleep per night on three or more
nights per week. Obtaining more than 9 hours of
sleep per 24 hour period (i.e., nighttime sleep plus
daytime napping), 3 or more nights per week
– More than 2.78 h of variability in sleep-wake
schedule across 1 week
– Bedtime later than 2:00 a.m. on three or more
nights per week
 Having a guaranteed bed to sleep in for 3 months
 Receiving care for SMI at ACBHCS and consent to
regular communications between research team and
psychiatrist and/or case manager
Exclusion criteria
The exclusion criteria are as follows:
Table 1 SPIRIT checklist
Time point Study period
Enrollment Pretreatment
assessment
Allocation Postallocation
Intervention Post-Treatment Assessment 6-Month follow-up
Enrollment
Eligibility screen X
Informed consent X X
Allocation X
Intervention
TranS-C X
UC-DT1
Data collection
Demographics X X X
Primary outcomes X X X
Secondary outcomes X X X
Diagnostic measures X X X
Sleep/insomnia history X
Medication tracking X X X X
Credibility/expectancy X
Abbreviations: TranS-C Transdiagnostic Intervention for Sleep and Circadian Dysfunction, UC-DT Usual care followed by delayed treatment with Transdiagnostic
Intervention for Sleep and Circadian Dysfunction.1Allocation to TranS-C after 6-months of usual care.
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 Presence of an active and progressive physical illness
or neurological degenerative disease and/or
substance abuse/dependence making participation in
the study infeasible
 Current serious suicide risk (assessed by our staff, a
case manager, or a psychiatrist) or homicide risk
(assessed by our staff, a case manager, or a psychiatrist)
 Night shift work >2 nights per week in the past
3 months
 Pregnancy or breastfeeding
 Not able/willing to participate in and/or complete
the pretreatment assessments
For the present study protocol, SMI is operationalized
according to U.S. Public Law 102-321 and previous re-
search [84–86] as the presence, for 12 months, of at
least one DSM-5-defined mental disorder that leads to
substantial interference with one or more major life
activities [87].
Sleep apnea and periodic limb movement disorder are
often comorbid with insomnia [88, 89], and individuals
with these sleep disorders typically have poor sleep
habits. Hence, we elected to include these individuals.
Indeed, there is already some evidence that these partici-
pants benefit from CBT-I [63, 90].
Pharmacotherapy for SMI is a complex undertaking
guided both by empirical evidence and by the specific
experiences and responses of individual participants.
Excluding participants whose medications need to be
changed is neither feasible nor representative of clinical
practice [91]. Medication use and changes will be re-
corded. All medication decisions will ultimately rest with
the treating physican and participant.
Measures
In addition to demographics (age, contact information,
sex, race/ethnicity, family, education, employment, living
arrangements, government assistance, housing), the
measures described in the subsections below will be
administered.
Primary outcomes
Functional impairment is assessed with the Sheehan
Disability Scale [92], which is a widely used brief
measure. The DSM-5 Cross-Cutting Measure is used as
a measure of disorder-focused symptoms. Sleep and cir-
cadian function is assessed with the Patient-Reported
Outcomes Measurement Information System–Sleep
Disturbance (PROMIS-SD) [93, 94] and the Patient-
Reported Outcomes Measurement Information System–
Sleep-Related Impairment (PROMIS-SRI) [93, 94], which
are brief, comprehensive, and well-validated. The
PROMIS scales are also administered at session 4 for the
mediation analysis.
Secondary outcomes
Impairment is assessed with the self-administered
version of the World Health Organization Disability
Assessment Schedule 2.0 and the 4-question healthy days
core module developed by the Centers for Disease Control
and Prevention [95]. Disorder-focused symptoms are
assessed using the Quick Inventory of Depressive Symp-
toms [96]; the Alcohol, Smoking and Substance Involve-
ment Screening Test [97]; and the Psychotic Symptoms
Rating Scales [98]. Sleep and circadian function is assessed
with the daily sleep diary and actigraphy, collected for
7 days at each assessment point. The outcomes to be ana-
lyzed using the sleep diary are the mean and variability in
sleep efficiency (total sleep time/time in bed × 100), total
sleep time (TST), total wake time (TWT), bedtime, wake
time, and rise time. In addition, nap duration will be cal-
culated. The actigraphy outcomes to be analyzed are the
means and variability for TST and TWT, as well as the
daytime activity count. In addition, we will calculate a
composite sleep health score [82], which is defined as the
sum of scores on six sleep health dimensions: regularity
(midpoint fluctuation across the 7-day sleep diary), satis-
faction (sleep quality question on PROMIS-SD), alertness
(daytime sleepiness question on PROMIS-SRI), timing
(mean midpoint across the 7-day sleep diary), efficiency
(sleep efficiency based on the 7-day sleep diary), and dur-
ation (TST based on 7-day sleep diary). This measure is
proposed to capture the complexity of the sleep problems
covered by TranS-C.
Other measures
The diagnostic measure used for mental disorders is
the M.I.N.I. International Neuropsychiatric Interview
(MINI) (version 7.0.0, including schizophrenia and psych-
otic disorders). The MINI is included as an evaluation of
the presence of current and past SMI. The MINI was de-
veloped to meet the need for a simple, short, but accurate
structured psychiatric interview. Its validity has been well-
supported [99–101]. At each assessment, we will report
the number of DSM-5 diagnoses derived from the MINI.
The diagnostic measure we will use for sleep disorders is
the Duke Structured Interview for Sleep Disorders
(DUKE) [102].
Sleep/insomnia history is obtained with the Sleep and
Circadian Problems Interview, which is an adapted version
of the Insomnia Interview Schedule [103]. To improve
our ability to identify obstructive sleep apnea, we will
supplement the proposed DUKE assessment with the
STOP-BANG Questionnaire [104], which is an 8-item
screen for obstructive sleep apnea. Both measures are
well-validated and widely used. Those suspected to
have another sleep disorder will receive nonstudy
evaluation/treatment and will not be excluded. At each
assessment, we will report the number of sleep
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diagnoses derived from the DUKE. The medication
tracking log will be used to record the treatments pa-
tients are receiving. Treatment credibility/expectancy is
administered at session 2 via the Credibility/Expectancy
Questionnaire [105, 106].
Treatments
TranS-C
TranS-C is administered by master’s-level therapists
hired within the University of California, Berkeley, for
this study, who travel between the ACBHCS clinic sites.
As participants move through the treatment at different
rates, TranS-C is provided in eight weekly 50-minute
sessions. If patients need additional sessions to cover the
treatment, up to four additional sessions may be offered
(i.e., maximum of 12 sessions). TranS-C includes four
cross-cutting interventions featured in every session;
four core modules that apply to the vast majority of
participants; and seven optional modules used less com-
monly, depending on the presentation. Table 2 summa-
rizes the approach.
Usual care followed by delayed treatment with TranS-C
The aim of the choice to compare TranS-C with UC-DT
is to strike a balance between (a) including a comparison
group to test the effectiveness of TranS-C in community
settings, information critical to determining the potential
of TranS-C for broader dissemination; and (b) ensuring
that all participants receive what is hypothesized to be a
more active treatment (TranS-C). Usual care in ACBHCS
starts with a case manager who coordinates care and
refers each client for a medication review and to various
rehabilitation programs (e.g., health care, housing, nutri-
tion, physical activity, finding a job, meditation group,
tobacco cessation group, peer monitoring). The content of
usual care will be monitored using the medication and
other treatment tracking logs. As depicted in Fig. 1, at the
end of 8 months in UC-DT, the participants will receive 8
to 12 sessions of TranS-C.
Treatment implementation and monitoring
Clinicians attend a one-day workshop, use a treatment
manual and receive weekly supervision to standardize
treatment administration. Treatment sessions are audio-
taped, and a random selection are rated using the Cogni-
tive Therapy Scale [107], which is a measure of general
intervention skills and CBT-specific skills.
Data analysis
Preliminary data evaluation
Missing or aberrant data will be verified. Data will be
audited for quality and completeness. We will detect out-
liers by evaluation of distributions and ensure that as-
sumptions of planned analyses are met. Prior to hypothesis
testing, appropriate statistical tests will be used to examine
baseline differences between groups (e.g., race/ethnicity,
age, sex, education, employment, psychiatric and medical
comorbidities). These tests will not be used to select covar-
iates in the primary intention-to-treat analysis [108–110].
Table 2 Summary of the Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Cross-cutting modules introduced
in sessions 1-3 (and featured in all
sessions thereafter)
Module Topics in TranS-C Treatment module
Case formulation Establishing regular sleep-wake times Core module 1, part a
Education Learning a wind-down routine Core module 1, part b
Behavior change and motivation Learning a wake-up routine Core module 1, part c
Goal-setting Improving daytime functioning Core module 2
Correcting unhelpful sleep-related beliefs Core module 3
Improving sleep efficiency Optional module 1
Reducing time in bed Optional module 2
Dealing with delayed or advanced phase Optional module 3
Reducing sleep-related worry/vigilance Optional module 4
Promoting compliance with CPAP/exposure
therapy for claustrophobic reactions to CPAP
Optional module 5
Negotiating sleep in a complicated
environment
Optional module 6
Reducing nightmares Optional module 7
Maintenance of behavior change Core module 4
Abbreviations: CPAP Continuous positive airway pressure, SMI Severe mental illness, TranS-C Transdiagnostic Intervention for Sleep and Circadian Dysfunction
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Instead, the potential influences of baseline differences will
be evaluated as moderators (described below).
Management of missing data
Recruiting 120 participants allows for attrition as per the
power calculation below. In longitudinal analyses, we will
use all available data and produce valid inferences if attri-
tion depends on treatment group or on previous out-
comes for the same participant [111]. If dropout is related
to other variables, these data will be included as predictors
to reduce any bias due to nonrandom missing data.
Main aim
TranS-C will be superior to UC-DT for reducing func-
tional impairment and disorder-focused symptoms, and
for improving sleep and circadian functioning, at post-
treatment and 6-month follow-up on primary outcomes.
To address these aims, we will test whether there are
differences in the mean trajectories across time points
between TranS-C and UC-DT using hierarchical linear
modeling (HLM) [112–114]. The first-level equation will
represent within-person variation and will include time
indicators (or dummy variables) as predictors (posttreat-
ment, 6-month follow-up assessment, with baseline as a
reference). The second-level equation represents between-
person variation in the intercept and coefficients of the
time indicators, and will include a dummy variable for
arm (TranS-C vs. UC-DT) as the predictor variable. Inter-
actions between arm and time indicators will be retained
only if found to be significant at the 5% level. A significant
interaction between arm and a time indicator suggests
that there are different trajectories of change in outcome
across time for each arm, and will be displayed as a graph
to interpret the interaction.
Exploratory analyses
For the exploratory analyses, we will use only the
primary outcome measures for impairment, disorder-
focused symptoms, and sleep and circadian function:
1. Do improved sleep and circadian functioning predict
reduced functional impairment and disorder-focused
symptoms from baseline to posttreatment? We will
use HLM to test whether changes in sleep and
circadian functioning predict changes in functional
impairment and disorder-focused symptoms from
baseline to posttreatment.
2. Do improved sleep and circadian functioning
mediate intervention effects on primary outcomes?
We will conduct mediation analysis using product
of coefficients, a powerful method for estimating
indirect effects [115]. The mediator will be sleep and
circadian functioning measured at session 4, and
outcomes will be functional impairment and
disorder-focused symptoms measured at
posttreatment.
3. Are intervention effects moderated by risk factors,
including demographics, symptom severity,
medications, and psychiatric and medical
comorbidities? We will conduct moderation analysis
by testing a three-way interaction of treatment arm,
time, and the moderator variable in the second-level
equation using the HLM model described above
[116, 117]. A significant coefficient for the arm ×
time ×moderator interaction would indicate a
moderating effect and will be followed with graphs
to interpret the modification [116].
A statistical significance level of 0.05 will be used
throughout.
Power analysis
Average effect size across outcomes akin to those
proposed were drawn from prior research [56, 79, 80]
(0.60). Using G*Power 3.1.7 software, 80% power, and a
two-tailed alpha of 5%, we will need 92 participants to
detect group differences. An additional 30% to account
for potential attrition yields 120 participants.
Discussion
The study protocol addresses several research priorities.
First, this study provides a test of a treatment that
addresses an important and understudied mechanism—
dysregulated sleep and circadian rhythms—in SMI. It
also addresses an understudied conceptual framework,
namely that sleep and circadian dysfunction contributes
to vicious cycles of escalating symptoms, vulnerability,
and risk in SMI. Second, this study provides a test of a
transdiagnostic treatment designed to treat a wide range
of sleep and circadian problems experienced by adults
with a wide range of SMIs. As such, the study contrib-
utes to the goal of developing interventions that use
broad, dimensional approaches to assessment and inter-
vention [118, 119]. Third, the sleep health framework
[82] that underpins the approach is relatively new. This
approach emphasizes the identification and treatment of
sleep disorders as well as the universal attributes of sleep
that can be optimized to promote well-being. Fourth,
the modular design of TranS-C, as well as the personal-
ized behavioral “prescriptions,” are responsive to the
calls to “develop a personalized approach to the diverse
needs and circumstances of people with mental illness”
[120, page 128]. Finally, this study will be conducted in a
community setting. Conducting the study in a community
setting contributes to the goal of bridging the gap between
research and practice and testing treatments in the
community. If the study is successful, this research will
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establish the potential for widespread dissemination of
TranS-C to improve SMI outcomes in the community.
Trial status
The trial is funded for 4 years. A ‘skeleton’ research staff
team started setting up the study in February 2015.
Patients began to be randomized in July 2015. The treat-
ment phase will be completed in July 2018. Final
outcome assessments will be complete by January 2019.
As of November 2016, 70 participants of the required
120 had been enrolled.
Additional files
Additional file 1: Completed SPIRIT checklist of recommended items to
address in a clinical trial protocol. (PDF 109 kb)
Additional file 2: Consent form. (PDF 63 kb)
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